Core Insights - CG Oncology announced promising results from the Phase 3 BOND-003 study of cretostimogene, showing that 75.5% of patients achieved a complete response at any time [1] - The median duration of response exceeds 28 months, indicating long-lasting efficacy [1] - No close contact precautions are necessary post-treatment, enhancing the treatment's practicality [2] Study Results - In the BOND-003 study, 83 out of 110 patients (75.5%) achieved a complete response, with 46% remaining in complete response at 12 months and 30 confirmed responses at 24 months [1] - The data presented at the EAU Congress indicates that cretostimogene levels peaked immediately after instillation and were sustained locally for 4-5 days, with no systemic exposure [2] - The most common treatment-related adverse events (TRAEs) were bladder spasm, pollakiuria, micturition urgency, dysuria, and hematuria, with a median resolution time of one day for any grade of TRAEs [3] Safety and Efficacy - No Grade 3 or greater treatment-related adverse events or deaths were reported, and 97.3% of patients completed all expected treatments, demonstrating high adherence [3] - Cretostimogene is an investigational oncolytic immunotherapy being evaluated for high-risk non-muscle invasive bladder cancer (NMIBC) patients unresponsive to BCG therapy [4][5] Company Overview - CG Oncology is focused on developing and commercializing innovative therapies for bladder cancer, aiming to improve patient quality of life [6]
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy